Reiter C, Frhlich T, Zeino M, et al. New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene hybrids[J]. Eur J Med Chem, 2015, 97: 164-172.
] Li Z, Shi X, Liu J, et al. Artesunate prevents type 1 diabetes in NOD mice mainly by inducing protective IL-4-producing T cells and regulatory T cells[J]. FASEB J, 2019, 33(7): 8241-8248.
[4]
] Yu L, Chen J F, Shuai X, et al. Artesunate protects pancreatic beta cells against cytokine-induced damage via SIRT1 inhibiting NF-κB activation[J]. J Endocrinol Invest, 2016, 39(1): 83-91.
[5]
] Li J, Casteels T, Frogne T, et al. Artemisinins target GABAA receptor signaling and impair α cell identity[J]. Cell, 2017, 168(1-2): 86-100,e15.
[6]
] van der Meulen T, Lee S, Noordeloos E, et al. Artemether does not turn α Cells into β cells[J]. Cell Metab, 2018, 27(1): 218-225, e4.
[7]
] Gnudi L, Richard J, Long D A. Diabetic nephropathy: perspective on novel molecular mechanisms[J]. Trends Endocrinol Metab, 2016, 27(11): 820-830.
[8]
] Lim A K, Tesch G H. Inflammation in diabetic nephropathy[J]. Mediators Inflamm, 2012, 2012: 146154.
[9]
] Bai L, Li J, Li H, et al. Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-κB signaling and NLRP3 inflammasome activation by exosomes in rats[J]. Biochem Pharmacol, 2019, 169: 113619.
[10]
Bai L, Li H, Li J, et al. Immunosuppressive effect of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via regulating the differentiation of CD4+ T cell subsets in rats[J]. Int Immunopharmacol, 2019, 70:313-323.
[11]
Wen Y, Pan M M, Lv L L, et al. Artemisinin attenuates tubulointerstitial inflammation and fibrosis via the NF-κB/NLRP3 pathway in rats with 5/6 subtotal nephrectomy [J]. J Cell Biochem, 2019, 120(3): 4291-4300.
Zhang Y, Li H, Zhu J, et al. Role of artesunate in TGF-β1 induced renal tubular epithelial mesenchymal transdifferentiation in NRK-52E cells[J]. Mol Med Rep, 2017, 16(6):8891-8899.
[17]
Han P, Wang Y, Zhan H, et al. Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice[J]. Am J Transl Res, 2019, 11(3): 1389-1402.
Lee I S, Ryu D K, Lim J, et al. Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells[J]. Neurosci Lett, 2012, 509(1):17-21.
Ahmad W, Khan I, Khan M A, et al. Evaluation of antidiabetic and antihyperlipidemic activity of Artemisia indica linn (aeriel parts) in Streptozotocin induced diabetic rats [J]. J Ethnopharmacol, 2014, 151(1): 618-623.
Gu Y, Wang X, Wang X, et al. Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway[J]. Tohoku J Exp Med, 2012, 227(3):161-170.
[24]
Xiong Z, Sun G, Zhu C, et al. Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling[J]. Eur J Pharmacol, 2010, 649(1-3): 277-284.
2020, Vol. 31 
